Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone269-389-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.60 billion
Profitability
Miscellaneous
Employees36,000
Next Earnings Date10/24/2019 (Estimated)
OptionableOptionable
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker announced a quarterly dividend on Wednesday, July 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.52 per share on Thursday, October 31st. This represents a $2.08 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Friday, September 27th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) posted its earnings results on Thursday, July, 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.93 by $0.05. The medical technology company earned $3.65 billion during the quarter, compared to analysts' expectations of $3.60 billion. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The company's revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $1.76 earnings per share. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker updated its FY19 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $8.15-8.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.15.
What price target have analysts set for SYK?
22 analysts have issued 12-month price targets for Stryker's stock. Their predictions range from $156.75 to $240.00. On average, they anticipate Stryker's stock price to reach $214.3875 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 5 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
Has Stryker been receiving favorable news coverage?
Media stories about SYK stock have been trending positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stryker earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news stories about the medical technology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Stryker.
Are investors shorting Stryker?
Stryker saw a decline in short interest in July. As of July 31st, there was short interest totalling 3,115,300 shares, a decline of 9.0% from the June 30th total of 3,423,200 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is currently 3.0 days. Currently, 0.9% of the company's stock are sold short. View Stryker's Current Options Chain.
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Novocure (NVCR), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART) and Globus Medical (GMED).
What other stocks do shareholders of Stryker own?
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 54)
- Mr. Timothy J. Scannell, Pres & COO (Age 54)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 57)
- Mr. Michael D. Hutchinson, VP & Chief Legal Officer (Age 48)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 57)
Who are Stryker's major shareholders?
Stryker's stock is owned by a number of of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.59%), Vanguard Group Inc. (7.15%), BlackRock Inc. (6.54%), BlackRock Inc. (6.54%), Greenleaf Trust (5.94%) and Bank of New York Mellon Corp (1.88%). Company insiders that own Stryker stock include Allan C Golston, Bijoy Sagar, David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Roch Doliveux, Srikant M Datar, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which major investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., BlackRock Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Winslow Capital Management LLC, Invesco Ltd. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Stryker company stock in the last year include Allan C Golston, Bijoy Sagar, Glenn S Boehnlein, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, M Kathryn Fink, Michael Damon Hutchinson, Srikant M Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.
Which major investors are buying Stryker stock?
SYK stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Vanguard Group Inc., Janus Henderson Group PLC, Janus Henderson Group PLC, Natixis, Natixis, First Trust Advisors LP and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $214.10.
How big of a company is Stryker?
Stryker has a market capitalization of $80.09 billion and generates $13.60 billion in revenue each year. The medical technology company earns $3.55 billion in net income (profit) each year or $7.31 on an earnings per share basis. Stryker employs 36,000 workers across the globe.View Additional Information About Stryker.
What is Stryker's official website?
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
